NDC product
Ganirelix Acetate
NDC 0548-5001 · Amphastar Pharmaceuticals, Inc.
Key facts
| Product NDC | 0548-5001 |
|---|---|
| Proprietary name | Ganirelix Acetate |
| Nonproprietary name | Ganirelix Acetate |
| Substances | GANIRELIX ACETATE |
| Dosage form | INJECTION |
| Route | SUBCUTANEOUS |
| Labeler | Amphastar Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA212613 |
| Pharmacologic classes | Decreased GnRH Secretion [PE], Gonadotropin Releasing Hormone Receptor Antagonist [EPC], Gonadotropin Releasing Hormone Receptor Antagonists [MoA] |
| Marketing start | Jun 20, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: